Senior officers of Triangle Angel Partners and Rubicon Venture Capital released a joint statement today in support of Carpe, a direct-to-consumer skincare brand in which both firms recently invested, citing a growing trend of successful startups offering solutions to often stigmatized maladies. Carpe, which produces products to combat hyperhidrosis (or excessive sweating), recently closed a $2.3 million seed round.
Carpe Antiperspirant Hand Lotion and Carpe Antiperspirant Foot Lotion
Speaking of the investment, Rubicon Venture Capital general partner Andrew Romans said, “Carpe has made a breakthrough product that is exactly what a specific segment of the human population needs. Now is the time to deploy a blended business model of partnering with large drug store and retail chains combined with a direct-to-consumer subscription model to address conditions that have traditionally been stigmatized. We believe Carpe will have the same impact for hyperhidrosis that companies like Roman and hims have done for conditions like hair loss and erectile dysfunction.”
John Stump, president at Triangle Angel Partners, commented that, “It’s exciting to see a high-growth startup like Carpe emerging from North Carolina’s burgeoning startup ecosystem. We believe that they are positioned to quickly become the preeminent hyperhidrosis solution in the United States, and eventually for the 365 million people globally who suffer from the disorder.”
Carpe was founded as a side project by then-college-sophomores David Spratte and Kasper Kubica in 2015, when the pair began developing a product to manage their hyperhidrosis. After graduating in 2017, Spratte and Kubica devoted their full-time efforts to the enterprise, and quickly sought funding.
The seed round, which closed on April 16th of 2018, will be used to expand the brand’s presence in the United States, and to develop additional products for the hyperhidrosis market.
Carpe is an antiperspirant lotion designed to reduce embarrassing hand and foot sweat, especially in patients with hyperhidrosis – an often neglected condition characterized by excessive sweating. It’s perfect for discreetly combating clammy hands in virtually any scenario – on dates, at business meetings, and even on the tennis court or golf course. Carpe’s proven formula, which was specifically formulated for maximum efficacy with no irritation, is gentle enough for prolonged daily use, and strong enough to help manage the symptoms of hyperhidrosis. Learn more at CarpeLotion.com
About Triangle Angel Partners
Triangle Angel Partners (TAP), based in Research Triangle Park, invests in technology-based companies from early seed through Series A and B stages. TAP brings experienced C-level talent with deep operating experience across a variety of sectors and geographies. TAP partners with entrepreneurs by investing committed capital and providing relevant expertise, advice and introductions for entrepreneurs.
About Rubicon Venture Capital
Rubicon Venture Capital is a bi-coastal San Francisco – New York fund focused on backing deep technology companies at the Late Seed, Series A and B stages. Rubicon is backed by a diverse set of value added LP investors including high-net worth individuals, family offices, corporations and institutional LPs located worldwide as well as the Research Triangle Park Area.
Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million
CAMBRIDGE, Mass., March 14, 2018 /PRNewswire/ — Flagship Pioneering, a unique life science innovation enterprise, today unveiled Foghorn Therapeutics. Foghorn uses its proprietary Gene Traffic Control™ product platform to discover and develop drugs based on novel insights into the chromatin regulatory system. The chromatin regulatory system directs gene expression in cells. Cigall Kadoch, Ph.D., of the Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute; Douglas Cole, M.D., of Flagship Pioneering; and Gerald Crabtree, M.D., of the Howard Hughes Medical Institute and Stanford University founded Foghorn to develop treatments for cancer and other serious diseases. Adrian Gottschalk, formerly senior vice president and neurodegeneration therapeutic area head at Biogen, is the company’s CEO. Flagship Pioneering developed and launched Foghorn through its innovation foundry, Flagship VentureLabs®. Flagship Pioneering has made an initial capital commitment of $50 million.
Since establishing operations in 2016, Foghorn Therapeutics has developed a product platform that has generated new insights into disease, created six programs, and built a discovery engine that is yielding many additional targets. The company is in the process of developing drug candidates across a range of cancers and is exploring applications of Gene Traffic Control in neurology and immunology.
About Foghorn Therapeutics
A Flagship Pioneering company, Foghorn was founded in 2016 by Cigall Kadoch, Ph.D., Gerald Crabtree, M.D., and Douglas Cole, M.D., of Flagship Pioneering. With Gene Traffic Control™, Foghorn is pioneering a new major class of drug targets to develop unprecedented therapies for cancer and other serious diseases.
Foghorn has a broad platform based on the fundamental biology of Gene Traffic Control. With this powerful platform, Foghorn has already developed new insights, rapidly advanced six programs, and created a discovery engine that will simultaneously yield many additional targets. With insights from Foghorn’s scientific founders, seasoned board and leadership team, and discovery engine, this is only the beginning of an entirely new approach to controlling gene expression. Learn more about Foghorn at www.foghorntx.com.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies. Its institutional innovation foundry, Flagship VentureLabs®, is where Flagship’s team of scientific entrepreneurs systematically evolves enterprising ideas into new fields or previously undiscovered areas of science into real-world inventions and ventures. Since its launch in 2000, the firm has applied its hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $20 billion in aggregate value, thousands of patents, and more than 60 clinical programs for novel therapeutic agents.
Beyond contributing foundational innovations and company entrepreneurial leadership, Flagship has also capitalized its growing ecosystem of first-in-class companies with over $1.2 billion coming from its $2.3 billion of capital commitments. An additional $7 billion has been co-invested into Flagship’s ecosystem to support growth. The firm’s current ecosystem includes pioneering ventures that are transforming human health and sustainability, including Denali Therapeutics (NASDAQ: DNLI), Editas Medicine (NASDAQ: EDIT), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies, including Evelo Biosciences, Kaleido Biosciences, Indigo Agriculture, CiBO Technologies, Rubius Therapeutics, Torque Therapeutics, and Moderna Therapeutics. Flagship has ongoing corporate innovation alliances with several market leaders, including AstraZeneca, the Crop Science Division of Bayer, and Nestlé Health Science. To learn more about Flagship Pioneering, please visit our website: www.FlagshipPioneering.com.
SOURCE Flagship Pioneering